BAQSIMI (glucagon nasal powder)

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals leverages proprietary intranasal, inhalation, and injectable delivery platforms to address niche, high-value markets. The company’s flagship product BAQSIMI® is the only dry nasal glucagon spray for severe hypoglycemia and holds the leading prescription share in the U.S. glucagon market. Backed by six FDA-registered facilities in the United States and a robust pipeline of complex generics and biosimilars, Amphastar is expanding its footprint in endocrinology, pulmonology, and nephrology. Strategic acquisitions, such as the purchase of BAQSIMI from Eli Lilly for $1 billion, underscore its commitment to capturing durable, revenue-generating assets.

Therapeutic Areas

Other Severe hypoglycemia Drugs